Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Invest New Drugs. 2013 Jul 26;31(5):1201–1206. doi: 10.1007/s10637-013-0004-2

Table 3.

Follow up details

Overall (N=14) Dose Level 1 (N=8) Dose Level 2 (N=6)
Number cycles received, median(range) 2 (1,5) 2 (2,5) 3 (1,4)
Follow-up Status
 Alive 9 (64.3%) 5 (62.5%) 4 (66.7%)
 Dead 5 (35.7%) 3 (37.5%) 2 (33.3%)
Progression Status
 Yes 10 (71.4%) 7 (87.5%) 3 (50%)
 No 4 (28.6%) 1 (12.5%) 3 (50%)
Off Active Treatment
 Yes 14 (100%) 8 (100%) 6 (100%)
Reason End Treatment
 Progression Onstudy 10 (71.4%) 7 (87.5%) 3 (50%)
 Refused Further Rx 1 (7.1%) 1 (12.5%) 0 (0%)
 AEs/Side Effects 3 (21.4%) 0 (0%) 3 (50%)